Literature DB >> 2941933

Possible role of ADP-ribosylation of adenovirus core proteins in virus infection.

C V Déry, G de Murcia, D Lamarre, N Morin, G G Poirier, J Weber.   

Abstract

We have investigated the role of poly(ADP)-ribosylation of adenoviral proteins in virus infection. Viral core proteins V and the precursor to protein VII were shown to be in vivo and in vitro acceptors of ADP-ribose. In vivo ADP-ribosylation was restricted to viral proteins as the histones were not labeled during the late phase of infection. The ADP-ribosylated core proteins were assembled into mature virus particles. In vitro ADP-ribosylation of adenoviral core proteins performed with purified poly(ADP-ribose) polymerase led to relaxation of the chromatin structure of both ts1 and wild type pyridine cores and pentonless particles and triggered the complete dissociation of wild type particles. A critical role for poly(ADP)-ribosylation in virus infection was confirmed by measuring the effect of the inhibitors 3-aminobenzamide and nicotinamide on virus particle yield and infectivity. Both inhibitors depressed particle yield by up to 9-fold, but infectivity was reduced by up to 10(4)-fold. These results suggest that ADP-ribosylation of adenovirus core proteins may have a role in virus decapsidation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941933     DOI: 10.1016/0168-1702(86)90078-x

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  Stepwise loss of fluorescent core protein V from human adenovirus during entry into cells.

Authors:  Daniel Puntener; Martin F Engelke; Zsolt Ruzsics; Sten Strunze; Corinne Wilhelm; Urs F Greber
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

2.  Identification of the gene coding for the precursor of adenovirus core protein X.

Authors:  J M Weber; C W Anderson
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

3.  The abundant nuclear enzyme PARP participates in the life cycle of simian virus 40 and is stimulated by minor capsid protein VP3.

Authors:  Ariela Gordon-Shaag; Yael Yosef; Mahmoud Abd El-Latif; Ariella Oppenheim
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Hippocampal poly(ADP-Ribose) polymerase 1 and caspase 3 activation in neonatal bornavirus infection.

Authors:  Brent L Williams; Mady Hornig; Kavitha Yaddanapudi; W Ian Lipkin
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

5.  Virus-Host Interactions and the ARTD/PARP Family of Enzymes.

Authors:  Chad V Kuny; Christopher S Sullivan
Journal:  PLoS Pathog       Date:  2016-03-24       Impact factor: 6.823

Review 6.  The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions.

Authors:  Anthony R Fehr; Sasha A Singh; Catherine M Kerr; Shin Mukai; Hideyuki Higashi; Masanori Aikawa
Journal:  Genes Dev       Date:  2020-02-06       Impact factor: 11.361

7.  An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.

Authors:  Yiyue Ge; Tingzhong Tian; Suling Huang; Fangping Wan; Jingxin Li; Shuya Li; Xiaoting Wang; Hui Yang; Lixiang Hong; Nian Wu; Enming Yuan; Yunan Luo; Lili Cheng; Chengliang Hu; Yipin Lei; Hantao Shu; Xiaolong Feng; Ziyuan Jiang; Yunfu Wu; Ying Chi; Xiling Guo; Lunbiao Cui; Liang Xiao; Zeng Li; Chunhao Yang; Zehong Miao; Ligong Chen; Haitao Li; Hainian Zeng; Dan Zhao; Fengcai Zhu; Xiaokun Shen; Jianyang Zeng
Journal:  Signal Transduct Target Ther       Date:  2021-04-24

8.  Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants.

Authors:  Katherine E Zarn; Sierra A Jaramillo; Anthony R Zapata; Nathan E Stone; Ashley N Jones; Haley E Nunnally; Erik W Settles; Ken Ng; Paul S Keim; Steen Knudsen; Patricia M Nuijten; Aloys S L Tijsma; Christopher T French
Journal:  PLoS One       Date:  2022-09-14       Impact factor: 3.752

9.  Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression.

Authors:  Stefania Mattiussi; Italo Tempera; Giulia Matusali; Giulia Mearini; Luisa Lenti; Silvia Fratarcangeli; Luciana Mosca; Maria D'Erme; Elena Mattia
Journal:  Infect Agent Cancer       Date:  2007-10-11       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.